To donate by check, phone, or other method, see our More Ways to Give page.

×
SUBSCRIBE TO OUR FREE NEWSLETTER

SUBSCRIBE TO OUR FREE NEWSLETTER

Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.

* indicates required
5
#000000
#FFFFFF
Democrats Call on White House to Ensure Any Coronavirus Vaccine Is Not Profit-Making Venture for Big Pharma

Lawmakers are asking the Trump administration to think of the nation's health, not Big Pharma. (Photo: AP)

Democrats Call on White House to Ensure Any Coronavirus Vaccine Is Not Profit-Making Venture for Big Pharma

"We cannot allow Big Pharma to price gouge the fruits of Americans investments."

News

Illinois Congresswoman Jan Schakowsky led 45 of her colleagues in demanding in a letter to President Donald Trump Thursday that any vaccine developed by the federal government for the coronavirus strain that broke out in December in China be kept "accessible and affordable" and not used as a source of profit for Big Pharma.

"Because of the millions YOU have invested into federal coronavirus research, a vaccine could be in initial clinical trials within 3 months," tweeted Schakowsky. "We cannot allow #BigPharma to price gouge the fruits of Americans' investments."

In their letter, Schakowsky and her colleagues express their concerns over licensing of the vaccine to pharmaceutical companies, a move that could jeopardize access to the potentially life-saving treatment.

"We urge the Department of Health and Human Services (HHS) not to provide an exclusive license to any private manufacturer for a coronavirus vaccine or treatment in any government grants, contracts, or licensing arrangements," the members say in the letter.

"Providing exclusive monopoly rights could result in an expensive medicine that is inaccessible, wasting public resources and putting public health at risk in the United States and around the globe," the letter continues. "If HHS or any other federal agency moves forward with such a proposal, we urge you to instead issue a limited license and implement requirements that a vaccine or treatment be made available at an affordable price."

As Common Dreams reported on February 13, the potential for a worldwide pandemic has countries around the world working together to contain the outbreak. While the rate of infection has slowed, cases worldwide jumped by around 15,000 in the last week to roughly 75,000--mostly concentrated in mainland China.

Progressives applauded the letter.

"Coronavirus vaccines and treatments must be made available to all--not used by #BigPharma as yet another opportunity to profit at patients' expense," said advocacy group Social Security Works.

In a tweet, Congressional pressure group Indivisible said the organization was "proud" to stand alongside Schakowsky and her colleagues.

"Medicines, like the coronavirus vaccine, that are developed with public money should benefit public health, not create private profit for Big Pharma," the group said.

Trade union the American Federation of State, County and Municipal Employees praised the 46 lawmaker signatories for making a point to ask about the role of public investment in the vaccine's development.

"Why should the federal government give monopoly rights to the drug corporations for the coronavirus vaccine currently being developed with taxpayer dollars?" the union tweeted. "Glad some folks in Congress are asking that question."

Why Your Ongoing Support Is Essential


Donald Trump’s attacks on democracy, justice, and a free press are escalating — putting everything we stand for at risk. We believe a better world is possible, but we can’t get there without your support.

Common Dreams stands apart. We answer only to you — our readers, activists, and changemakers — not to billionaires or corporations. Our independence allows us to cover the vital stories that others won’t, spotlighting movements for peace, equality, and human rights.

Right now, our work faces unprecedented challenges. Misinformation is spreading, journalists are under attack, and financial pressures are mounting. As a reader-supported, nonprofit newsroom, your support is crucial to keep this journalism alive.

Whatever you can give — $10, $25, or $100 — helps us stay strong and responsive when the world needs us most.

Together, we’ll continue to build the independent, courageous journalism our movement relies on. Thank you for being part of this community.

Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
covid-19house democratspandemicpoliticstrumpism

Illinois Congresswoman Jan Schakowsky led 45 of her colleagues in demanding in a letter to President Donald Trump Thursday that any vaccine developed by the federal government for the coronavirus strain that broke out in December in China be kept "accessible and affordable" and not used as a source of profit for Big Pharma.

"Because of the millions YOU have invested into federal coronavirus research, a vaccine could be in initial clinical trials within 3 months," tweeted Schakowsky. "We cannot allow #BigPharma to price gouge the fruits of Americans' investments."

In their letter, Schakowsky and her colleagues express their concerns over licensing of the vaccine to pharmaceutical companies, a move that could jeopardize access to the potentially life-saving treatment.

"We urge the Department of Health and Human Services (HHS) not to provide an exclusive license to any private manufacturer for a coronavirus vaccine or treatment in any government grants, contracts, or licensing arrangements," the members say in the letter.

"Providing exclusive monopoly rights could result in an expensive medicine that is inaccessible, wasting public resources and putting public health at risk in the United States and around the globe," the letter continues. "If HHS or any other federal agency moves forward with such a proposal, we urge you to instead issue a limited license and implement requirements that a vaccine or treatment be made available at an affordable price."

As Common Dreams reported on February 13, the potential for a worldwide pandemic has countries around the world working together to contain the outbreak. While the rate of infection has slowed, cases worldwide jumped by around 15,000 in the last week to roughly 75,000--mostly concentrated in mainland China.

Progressives applauded the letter.

"Coronavirus vaccines and treatments must be made available to all--not used by #BigPharma as yet another opportunity to profit at patients' expense," said advocacy group Social Security Works.

In a tweet, Congressional pressure group Indivisible said the organization was "proud" to stand alongside Schakowsky and her colleagues.

"Medicines, like the coronavirus vaccine, that are developed with public money should benefit public health, not create private profit for Big Pharma," the group said.

Trade union the American Federation of State, County and Municipal Employees praised the 46 lawmaker signatories for making a point to ask about the role of public investment in the vaccine's development.

"Why should the federal government give monopoly rights to the drug corporations for the coronavirus vaccine currently being developed with taxpayer dollars?" the union tweeted. "Glad some folks in Congress are asking that question."

Illinois Congresswoman Jan Schakowsky led 45 of her colleagues in demanding in a letter to President Donald Trump Thursday that any vaccine developed by the federal government for the coronavirus strain that broke out in December in China be kept "accessible and affordable" and not used as a source of profit for Big Pharma.

"Because of the millions YOU have invested into federal coronavirus research, a vaccine could be in initial clinical trials within 3 months," tweeted Schakowsky. "We cannot allow #BigPharma to price gouge the fruits of Americans' investments."

In their letter, Schakowsky and her colleagues express their concerns over licensing of the vaccine to pharmaceutical companies, a move that could jeopardize access to the potentially life-saving treatment.

"We urge the Department of Health and Human Services (HHS) not to provide an exclusive license to any private manufacturer for a coronavirus vaccine or treatment in any government grants, contracts, or licensing arrangements," the members say in the letter.

"Providing exclusive monopoly rights could result in an expensive medicine that is inaccessible, wasting public resources and putting public health at risk in the United States and around the globe," the letter continues. "If HHS or any other federal agency moves forward with such a proposal, we urge you to instead issue a limited license and implement requirements that a vaccine or treatment be made available at an affordable price."

As Common Dreams reported on February 13, the potential for a worldwide pandemic has countries around the world working together to contain the outbreak. While the rate of infection has slowed, cases worldwide jumped by around 15,000 in the last week to roughly 75,000--mostly concentrated in mainland China.

Progressives applauded the letter.

"Coronavirus vaccines and treatments must be made available to all--not used by #BigPharma as yet another opportunity to profit at patients' expense," said advocacy group Social Security Works.

In a tweet, Congressional pressure group Indivisible said the organization was "proud" to stand alongside Schakowsky and her colleagues.

"Medicines, like the coronavirus vaccine, that are developed with public money should benefit public health, not create private profit for Big Pharma," the group said.

Trade union the American Federation of State, County and Municipal Employees praised the 46 lawmaker signatories for making a point to ask about the role of public investment in the vaccine's development.

"Why should the federal government give monopoly rights to the drug corporations for the coronavirus vaccine currently being developed with taxpayer dollars?" the union tweeted. "Glad some folks in Congress are asking that question."

covid-19house democratspandemicpoliticstrumpism
Join the Conversation